4 trends tracked about this subject — the full history, oldest to newest below.
An FDA advisory panel has signaled support for easing restrictions on six specific peptides for compounding, sparking a debate over drug safety.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
An FDA advisory panel has voted to allow the compounding of unapproved peptides, signaling a potential conflict with agency scientists.
Federal regulators face mounting scrutiny over potential conflicts of interest ahead of an upcoming vote on peptide substances.